LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis by Odena, Gemma et al.
1Scientific RepoRts | 6:35610 | DOI: 10.1038/srep35610
www.nature.com/scientificreports
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Dominique Valla8, Fulton Crews4, Ekihiro Seki3, Pau Sancho-Bru2 & Ramon Bataller1,2,4
Alcoholic hepatitis (AH) is the most severe form of alcoholic liver disease for which there are no effective 
therapies. Patients with AH show impaired hepatocyte proliferation, expansion of inefficient ductular 
cells and high lipopolysaccharide (LPS) levels. It is unknown whether LPS mediates ductular cell 
expansion. We performed transcriptome studies and identified keratin 23 (KRT23) as a new ductular cell 
marker. KRT23 expression correlated with mortality and LPS serum levels. LPS-TLR4 pathway role in 
ductular cell expansion was assessed in human and mouse progenitor cells, liver slices and liver injured 
TLR4 KO mice. In AH patients, ductular cell expansion correlated with portal hypertension and collagen 
expression. Functional studies in ductular cells showed that KRT23 regulates collagen expression. These 
results support a role for LPS-TLR4 pathway in promoting ductular reaction in AH. Maneuvers aimed at 
decreasing LPS serum levels in AH patients could have beneficial effects by preventing ductular reaction 
development.
Alcoholic liver disease (ALD) is the main cause of cirrhosis worldwide1 and the main driver of health expenditure 
in hospitalized patients with liver disease in the US2. In clear contrast with the recent advances in viral hepatitis, 
there are no targeted therapies for patients with ALD. In particular, there are no effective therapies for alcoholic 
hepatitis (AH), a frequent and severe presentation of ALD patients that bears a high short-term mortality rate3. 
Mortality associated with AH is due to profound liver failure and portal hypertension, leading to complications 
such as variceal bleeding, renal failure and sepsis4,5. Patients with severe AH are particularly prone to bacterial 
infections, reflecting intense derangement of immune function6. The available therapy (i.e. prednisolone) does 
not improve survival beyond one month, and targeted therapies are urgently needed7–9. Identifying molecular 
and cellular drivers of AH is a prerequisite to develop such therapies. In fact, there is a current effort by public 
agencies in the US (i.e. NIH-sponsored international consortia on translational research in AH) to identify novel 
targets for therapy.
The pathogenesis of AH is largely unknown. Translational studies using human samples have identified sev-
eral potential molecular targets including the CXC chemokine family, tumor necrosis factor receptor superfamily 
member 12A, osteopontin, chemokine (C-C motif) ligand 20, members of the inflammasome, interleukin-22, the 
Hedgehog signaling pathway and macrophage migration inhibitory factor10–16. Moreover, gut-derived bacterial 
products such as lipopolysaccharide (LPS) are believed to play a major role by inducing liver inflammation and 
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fibrogenesis through toll-like receptor 4 (TLR4) expressed in both parenchymal and non-parenchymal cells17. 
Strategies aimed at modifying bacterial dysbiosis and ameliorating intestinal barrier dysfunction and the result-
ing translocation of endotoxin into the portal circulation may be beneficial in patients with AH18,19. We recently 
found that LPS serum levels predict mortality in patients with AH and are associated with a poor response to 
corticosteroids20. The mechanisms by which increased LPS levels are associated with a poor outcome are largely 
unknown. Human studies suggest that LPS could mediate immune paralysis in these patients and favor infec-
tions21,22. We hypothesize that LPS could also play a role in the impaired hepatocellular regeneration in these 
patients. Recent studies strongly suggest that an inefficient ductular reaction (mostly composed by liver progeni-
tor cells -LPC-) could play a role in AH23,24. Furthermore, markers of hepatic ductular reaction at admission cor-
relate with liver injury and closely predict short-term mortality in AH23 and patients non-responding to therapy 
show a massive expansion of ductular cells in the liver explants24. Little is known on the factors that regulate the 
growth and fate of ductular cells in the setting of AH. Investigating the biological properties of these cells could 
favor the development of novel targeted therapies for AH.
LPS is known to regulate the proliferation and fate in bone marrow, endothelial and dental progenitor cells 
through TLR4 signaling25–29. It is plausible that increased LPS levels also play a role in the expansion of inefficient 
ductular cells in AH. To test this hypothesis, we conducted a systems biology approach including a comparative 
transcriptome analysis of liver from patients with AH and non-alcoholic steatohepatitis (NASH) to find novel 
markers of ductular cells. The “structural molecule activity” pathway was found to be the most dysregulated 
pathway, and keratin 23 (KRT23) was the most upregulated gene in this family. Importantly, this keratin was 
expressed in the ductular reaction in humans and mice. Based on these recent data, we hypothesized that the 
LPS-TLR4 pathway may stimulate the expansion of ductular reaction and regulates the biological properties of 
ductular cells in AH.
Results
Identification of KRT23 as a Marker of Ductular Cells in AH. Comparative gene expression profile 
analysis was performed in patients with severe AH (n = 15, Table 1), NASH (n = 8, Supplementary Table 1) and 
normal controls (n = 7) that underwent microarray analysis in our lab11,30 in order to identify genes specifically 
dysregulated in this severe form of ALD. Unsupervised clustering analysis revealed a unique gene expression 
signature of livers from patients with AH compared to NASH (Fig. 1a). To visualize the main differences in global 
transcriptional patterns between the three study groups we performed multidimensional scaling analysis of the 30 
Characteristics Median (25–75 IQR)
Age (years) 52 (46–56)
Male n (%) 39 (76)
Corticosteroids n (%) 27 (53)
SIRS (%) 18 (35)
Laboratory and hemodynamic parameters
 Hemoglobin (g/dL) 17 (10–13)
 Leukocyte count x109/L 8.6 (6.3–12.6)
 Platelet count x109/L 119 (77–208)
 AST (U/L) 117 (66–152)
 ALT (U/L) 37 (23–60)
 Serum albumin (g/dL) 2.6 (2.3–3.2)
 Serum creatinine (mg/dL) 0.9 (0.6–1.1)
 Serum bilirubin (mg/dL) 6.7 (3.0–18.5)
 International normalized ratio 1.6 (1.4–1.8)
 Hepatic venous pressure gradient (mmHg) 19 (14–22)
Alcoholic hepatitis severity scores at admission
 MELD score 19 (14–24)
 ABIC score 7.3 (6.7–8.4)
 ABIC Class n (%)
  A 14 (27)
  B 31 (61)
  C 6 (12)
Clinical decompensations during hospitalization
 AKI n (%) 18 (35)
 Infection n (%) 17 (33)
Mortality at 90 days n (%) 10 (20)
Table 1.  Baseline characteristics of patients with AH. Note: The total series included 51 patients. Samples 
from 15 patients were used for microarray analysis. IQR, interquartile range; SIRS, Systemic inflammatory 
response syndrome; AKI, Acute kidney injury.
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samples that underwent array profiling (Fig. 1b). Importantly, marked differences in gene expression were noted 
between livers from patients with AH, patients with NASH and normal controls (P < 0.001). A Venn diagram 
illustrates different groups of genes differentially regulated in both diseases (Fig. 1c). We found the majority of 
genes were differentially dysregulated between AH and NASH (1,200 upregulated and 854 downregulated in AH 
vs. NASH, respectively). Additionally, 296 genes were similarly dysregulated in AH and NASH compared to nor-
mal livers, while a smaller group of genes were specifically dysregulated in NASH compared to AH (148 upregu-
lated and 102 downregulated, respectively). Functional analysis of the transcriptome data (GOstats) revealed key 
pathways differentially regulated in patients with AH when compared to NASH and control livers. Among these 
pathways, the “structural molecule activity” pathway was found to be the most significantly upregulated in AH 
Figure 1. Comparative Functional Analysis of the Transcriptome in AH and NASH. (a) Heatmap display of 
the genes with the most significantly different expression between patients with AH, patients with NASH and 
healthy controls. Rows represent genes, and columns represent samples. The intensity of each color denotes 
the standardized ratio between each value and the average expression of each gene across all samples. Red 
pixels correspond to an increased abundance of mRNA in the indicated liver biopsy sample, whereas green 
pixels indicate decreased mRNA levels. (b) Multidimensional scaling analysis representing the 30 samples 
that underwent array profiling. The different samples are placed in the three-dimensional space according to 
their mRNA expression. AH samples are represented in magenta, NASH in light blue and normal livers in red. 
(c) Venn diagram showing the overlapping genes that were significantly upregulated (red) or downregulated 
(green). Venn diagram shows genes specifically upregulated (1200 genes) or downregulated (854 genes) in 
AH as well as genes specifically upregulated (148 genes) or downregulated (102 genes) in NASH. (d) Heatmap 
display of keratins with the most significantly different expression between AH and NASH and control livers. 
The intensity of each color denotes the standardized ratio between each value and the average expression of each 
gene across all samples. Red pixels correspond to an increased abundance of mRNA in the indicated liver biopsy 
sample, whereas green pixels indicate decreased mRNA levels.
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(P = 7.5 × 10−9) (Supplementary Table 2). The most upregulated genes that were differentially regulated in this 
and other significant pathways between patients with AH and NASH are shown in Table 2.
Next, we sought to identify novel specific biomarkers exclusively overexpressed in patients with AH. We 
focused on the “structural molecule activity” pathway, the most dysregulated pathway in our functional analysis. 
Among the genes most upregulated in this pathway, we found several keratins (KRT23, keratin 19 -KRT19-, and 
keratin 7 -KRT7-) as well as genes encoding procollagens I-V (Table 2). Because keratins are novel biomarkers in 
liver disease that also regulate cell fate, we further analyzed this subgroup of genes. Figure 1c shows the expression 
of genes encoding keratins, which were markedly upregulated in AH. Among them, we found KRT23 to be the 
most upregulated gene in AH compared to NASH and normal livers (45.8 and 126-fold increase, respectively, 
P < 0.001 for both).
Based on previous studies from our lab showing that most upregulated genes in AH are ductular reaction 
markers23, we hypothesized that KRT23 is predominantly expressed in these cells. Immunohistochemistry stud-
ies in patients with AH, including double staining studies using two ductular reaction markers (KRT7, epithelial 
cell adhesion molecule -EPCAM-) clearly demonstrated that KRT23 is preferentially expressed in the ductular 
reaction cells in AH (Fig. 2a,b). KRT23 showed a strong overlap with KRT7 and co-localized in the same cell as 
EPCAM. KRT23 is also weakly expressed in some hepatoblasts in the vicinity of the ductular reaction. These 
results strongly suggest that KRT23 is mainly expressed in the ductular reaction (likely LPCs) in patients with AH.
Expression of KRT23 in Animal Models of Ductular Reaction. The current experimental models of 
ALD do not reproduce the main histological features of severe AH (i.e. advanced fibrosis, bilirrubinostasis and 
ductular reaction) that are associated with a poor outcome23,31,32 but rather mimic moderate alcoholic liver dis-
ease. To overcome this difficulty, we used different animal models of liver injury which reproduce unique features 
of AH. To explore the expression of KRT23 in the ductular reaction we used a well-characterized experimental 
model which causes advanced fibrosis, cholestasis and progenitor cell expansion (i.e. DDC diet). We found that 
KRT23 gene and protein expression were dramatically induced in DDC-treated mice. Interestingly, KRT23 pro-
tein was detected within the ductular reaction (Fig. 2c,d). To further confirm that KRT23 is expressed in LPCs, 
we analyzed hepatic gene expression of primary LPCs isolated from DDC-treated mice33. Expression of KRT23 
as well as specific cell markers of LPCs were significantly enriched in LPC cells vs. non-LPC population (Fig. 2e). 
Overall, these results indicate that KRT23 is expressed in the ductular reaction and LPCs in livers with cholestasis 
and progenitor cell expansion.
Accession N°
Gene name or 
Symbol
Fold 
Change Accession N°
Gene name or 
Symbol
Fold 
Change
Structural molecule activity Identical protein binding
NM_015515 Keratin 23 45.8 NM_005564 Lipocalin 2 11.1
NM_000089 Collagen, type I, α 2 10.1 NM_178859 SLC51B 6.3
K01228 Collagen, type I, α 1 8.1 AF133207 HSPB8 4.9
NM_002276 Keratin 19 7.1 NM_001673 ASNS 4.5
BC002700 Keratin 7 6.7
NM_001845 Collagen, type IV, α 1 6.3 Oxidoreductase activity
NM_002345 Lumican 6.0 NM_020299 AKR1B10 134.5
AU146808 Collagen, type III, α 1 4.6 AW190565 LOXL4 9.3
X05610 Collagen, type IV, α 2 4.6 BC001886 RRM2 6.6
M80927 Chitinase 3-like 1 4.5 NM_000903 NQO1 6.3
N30339 Collagen, type V, α 1 4.3 AY007239 MOXD1 4.9
NM_003956 CH25H 4.4
Chemokine activity
NM_002993 CXCL6 27.7 Enzyme inhibitor activity
NM_004591 CCL20 23.0 NM_003122 SPINK1 12.8
NM_000584 Interleukin 8 12.2 NM_020169 Latexin 5.6
S69738 CCL2 6.1 NM_003254 TIMP1 4.9
NM_001511 CXCL1 5.8 AL541302 SERPINE2 4.3
Calcium Ion binding Other functions
AI826799 EFEMP1 14.1 M83248 Osteopontin 24.7
NM_003247 Thrombospondin 2 8.9 NM_002423 MMP7 17.1
BF218922 Versican 7.5 NM_005764 PDZK1IP1 15.6
NM_005980 S100P 7.0 NM_002354 EPCAM 12.0
BC001388 Annexin A2 6.2 J04152 TACSTD2 10.9
NM_014624 S100A6 4.1 AW444617 DCDC2 10.8
Table 2.  Most relevant genes differentially expressed in patients with AH compared with patients with 
NASH. Results expressed in fold change of AH vs. NASH.
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Expression of KRT23-positive Ductular Cells in AH: Correlation with Disease Outcome. To con-
firm the microarray results, we analyzed KRT23 hepatic gene expression in a large cohort of patients with AH and 
other diseased controls by real time PCR. The results confirmed a dramatic upregulation of KRT23 in patients 
with AH (n = 51) compared with normal livers (n = 7) and other liver diseases including compensated cirrhosis 
Figure 2. Identification of KRT23 as a Marker of Ductular Cells in AH. (a) Representative micrographs 
of KRT23 protein expression in paraffin sections of liver biopsies from normal livers and from patients with 
AH, stained with anti-KRT23 antibody (x100 magnification). (b) Immunofluorescence staining shows co-
localization of KRT23 and LPCs markers (KRT7 and EPCAM) in paraffin sections of liver biopsies from 
patients with AH (x100 magnification). (c) Krt23 hepatic gene expression measured in a mouse model of 
progenitor cell expansion (DDC diet for 4 weeks, n = 6 compared to uninjured mouse liver (control, n = 6).  
(d) Representative images of liver KRT23 staining in mice treated for 4 weeks with a DDC diet and in uninjured 
mice (x200 magnification). (e) Krt23 and LPCs markers (Epcam, Krt7, Krt19) gene expression was significantly 
enriched in LCP cells (n = 3) vs. a non-LPC population (n = 3).
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(n = 10), hepatitis C (n = 10, HCV) and NASH (n = 14), (P < 0.001) (Fig. 3a). KRT23 expression was also upreg-
ulated, but to a lesser extent, in patients with HCV (P < 0.005) and compensated cirrhosis (P < 0.001) compared 
to the control liver samples. Elevated circulating levels of soluble keratin 18 have been detected in several liver 
diseases and may serve as a biomarker for identifying steatohepatitis34,35. We then assessed serum KRT23 con-
centration and plasma free and microparticle-bound proteins by ELISA as a potential biomarker of liver disease. 
KRT23 serum concentration was higher in patients with AH as compared to patients with compensated cirrhosis 
(Fig. 3b). Since other keratins (i.e. keratin 18) are typically bound to microparticles, we next explored whether 
KRT23 is also linked to these small molecules. We found that the vast majority of KRT23 in plasma was not 
bound to microparticles (Supplementary Fig. 1a,b).
To gain insight on the pathogenic role of KRT23-positive ductular cells in AH, we next explored whether 
its expression correlated with disease severity in the cohort of patients with AH (n = 51). KRT23 hepatic gene 
expression (expressed as fold change vs. normal livers) positively correlated with the main prognostic scores 
in patients with AH. Hepatic KRT23 correlated with Model for End-stage Liver Disease (MELD; P = 0.01) and 
Age/Bilirubin/International normalized ratio/Creatinine (ABIC; P = 0.01) scores (Fig. 3c). We also observed 
increased hepatic KRT23 mRNA levels in patients who died within 90 days after admission compared with 
those who survived (522-fold vs. 245-fold induction, respectively; P = 0.01). In addition, to evaluate if KRT23 
Figure 3. KRT23 expression correlates with disease severity and key features of AH. (a) KRT23 hepatic gene 
expression measured by qPCR in patients with AH (n = 51), HCV (n = 10), compensated cirrhosis (n = 10) and 
NASH (n = 14), compared to normal livers (n = 7). (b) KRT23 peripheral serum levels are elevated in patients 
with AH (n = 34) when compared to patients with cirrhosis (n = 14). (c) Correlation between KRT23 hepatic 
gene expression (fold change vs. normal livers) and clinical features in patients with AH (n = 51). Both MELD 
score as well as ABIC score correlated with KRT23 hepatic gene expression. (d) Kaplan-Meier’s curve analysis 
illustrates the relationship between KRT23 hepatic gene expression with 90-day mortality in patients with AH. 
A cut-off value of 250-fold expression (fold change vs. normal livers) defined patients with low and high KRT23 
gene expression with the best sensitivity and specificity. Portal hypertension (hepatic venous pressure gradient – 
HVPG – mmHg) was higher in patients with higher KRT23 gene expression levels (> 250-fold).
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can serve as a predictor of short-term mortality, we performed a Kaplan-Meier analysis. A value of 250-fold 
expression (fold expression vs. normal livers) was identified as the cut-off value with better sensitivity and spec-
ificity to define patients with low and high KRT23 gene expression (area under the receiver characteristic curve 
- AUROC = 0.72 [95% CI 0.51–0.91]). KRT23 hepatic gene expression predicted short-term mortality in patients 
with AH (Fig. 3d). Finally, we analyzed if KRT23 gene expression correlated with the degree of portal hyperten-
sion, a major pathophysiological event in these patients. We observed a higher degree of portal hypertension in 
patients with higher levels of hepatic KRT23 expression compared to those with lower levels of hepatic KRT23 
expression (hepatic venous pressure gradient 14 ± 6 mmHg vs. 21 ± 5 mmHg, respectively; P < 0.001) (Fig. 3d). 
Overall, these results suggest that KRT23-positive ductular cells may play a role in the pathophysiology of AH and 
that KRT23 might be used as a biomarker to predict short-term outcomes in patients with AH.
Role of LPS-TLR4 Pathway on Expression of KRT23-positive Ductular Cells. LPS plays a major 
role in several liver diseases36–39. Because LPS is a major driver in AH and correlates with patient outcome20, we 
next explored if LPS stimulates the expression of ductular cell makers using different experimental approaches. 
First, we showed that LPS serum levels strongly correlated with hepatic expression of KRT23 in patients with AH 
(P < 0.001, Fig. 4a). To uncover the mechanisms driving the increase of KRT23-positive ductular cells in AH, we 
used different animal models of liver injury which are representative of some of the key events that occur in AH, 
such as ethanol consumption, fibrosis and endotoxaemia. First, we showed that LPS administration markedly 
induced Krt23 expression in Balb/c mice (Fig. 4b). Then, we explored if LPS further increases the expression of 
Krt23 in livers with advanced fibrosis. To test this hypothesis we induced advanced fibrosis with chronic carbon 
tetrachloride (CCl4). As shown in Fig. 4c LPS administration further increased the expression for Krt23 in fibrotic 
livers. These results were confirmed in precision-cut liver slices (Supplementary Fig. 2a–h). Finally, we used a 
protocol to generate LPCs from pluripotent stem cells. Differentiation of these stem cells into LPCs resulted in 
the upregulation of keratins including KRT23 and KRT7 as well as EPCAM, a ductular reaction marker. Notably, 
expression of these markers was increased in cells incubated with LPS (Fig. 4d and Supplementary Fig. 3a–c). 
These results, together with the finding that LPS serum levels correlated with KRT23 expression in AH, strongly 
suggest that LPS could drive expression of KRT23-positive ductular cells.
Subsequently, we investigated whether TLR4 mediates the effect of LPS on the development of KRT23-positive 
ductular reaction. To test this hypothesis, we first found that TLR4 small interfering RNA (Tlr4 siRNA) 
blocked LPS-induced Krt23 in precision-cut liver slices (Supplementary Fig. 2a,b). Next, we performed in vivo 
loss-of-function studies using Tlr4 deficient mice. We first caused advanced fibrosis by inducing chronic cholesta-
sis through prolonged bile duct ligation (BDL), which is known to increase serum LPS levels40. Mice with BDL 
showed a marked upregulation of KRT23 (both at the gene and protein levels), KRT7, and EPCAM, all of which 
were heavily blunted in mice lacking TLR4 (Fig. 5a,b). To a lesser extent, these results were also observed in 
TLR4-KO mice chronically exposed to alcohol (Tsukamoto-French model) (Fig. 5c,d). Overall, these results sug-
gest that the LPS-TLR4 pathway mediates the development of ductular reaction and KRT23 expression in chronic 
liver injury.
Regulation of KRT23 Expression by Histone Acetylation in LPCs. Because ALD is characterized 
by profound epigenetic changes41 and KRT23 is sensitive to histone deacetylases (HDAC) inhibition42, we next 
investigated whether KRT23 expression in ductular cells is governed by histone acetylation in LPCs. First, we 
showed that an exogenous inhibitor of HDACs (sodium butyrate -NaB-) considerably increased Krt23 in bipo-
tential mouse adult liver cells (BAML) isolated from mice (Fig. 6a). We recently demonstrated that AH is charac-
terized by a distinct decrease of sirtuin 1 (SIRT1), a powerful HDAC43. To test if SIRT1 also plays a role in KRT23 
induction, we first investigated if NaB treatment on BAML cells is associated with a decrease in SIRT1 levels. As 
shown in Fig. 6b, SIRT1 levels are downregulated in this model. SIRT1 levels are also downregulated in the model 
of human LPC differentiation in culture (Supplementary Fig. 6a,b). The role of SIRT1 in inducing KRT23 expres-
sion was demonstrated in mice deficient for Sirt1 exposed to chronic ethanol (Supplementary Fig. 5a,b). The 
absence of Sirt1 in mice exposed to alcohol was associated with increased Krt23 expression. These results suggest 
that histone acetylation regulates KRT23 expression in LPCs.
Fibrogenic Roles of KRT23 in Ductular Cells. Because severe fibrosis is a hallmark find in AH that pre-
dicts survival in these patients31, and levels of KRT23 correlated with the degree of portal hypertension in patients 
with AH, we finally explored the potential fibrogenic role of KRT23 in ductular cells. We found that the expres-
sion of KRT23 closely correlated with the expression of collagen type I alpha 1 (COL1A1) (Fig. 6c). Since ductular 
cells express COL1A1, we next investigated if KRT23 stimulates profibrogenic actions in mouse BAML cells. 
BAML cells treated with NaB also showed Col1a1 over-expression in a Krt23-dependent manner (Fig. 6d), since 
this profibrogenic response was blunted in cells transfected with a Krt23 siRNA (Fig. 6e). Taken together, these 
results suggest that KRT23 may be promoting pro-fibrogenic actions in ductular cells.
Discussion
The current paradigm is that AH is due to a flare of hepatic inflammation caused by neutrophils in a previously 
damaged liver. However, we recently found that neutrophil infiltrate is associated with a better prognosis in AH31 
and that severe AH is characterized by poor hepatocellular function and an inefficient accumulation of ductular 
cells23,24. Therefore, our efforts are currently focused in finding the molecular drivers causing this massive accu-
mulation of ductular cells. To identify new markers of ductular cells, we used a highly translational approach. We 
first compared the transcriptome of patients with AH and NASH, and found that the “structural molecule activ-
ity” pathway was the most specifically dysregulated in patients with AH. A detailed analysis of this family of genes 
allowed us to identify several keratins that were profoundly upregulated in the livers with AH. Among them, we 
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Figure 4. KRT23 hepatic expression in animal models of liver injury and in LPCs. (a) Relationship between 
KRT23 hepatic gene expression and LPS serum levels in patients with AH (n = 39). Correlation between LPS 
serum levels and ABIC score in patients with AH. (b) Krt23 hepatic gene expression in a mouse model of acute 
liver injury. Krt23 gene expression in mice treated with LPS (n = 6) compared to control mice (n = 6). (c) Krt23 
hepatic gene expression in a mouse model of advanced fibrosis. Krt23 in mice treated CCl4 plus LPS (n = 8) 
compared to mice treated with CCl4 alone (n = 6). (d) Gene expression of KRT23 and LPCs markers (KRT7 and 
EPCAM) in a model of liver progenitor cell differentiation from 3 independent experiments.
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Figure 5. LPS-TLR4 induced liver damage is mediated by ductular cells in animal models of liver injury. 
(a) Gene expression of Krt23 and LPCs markers (Krt7 and Epcam) in WT and Tlr4-KO mice subjected to  
sham operation (n = 3) or BDL. BDL mice were sacrificed 5 (n = 4) or 21 days (n = 8) after operation.  
(b) Representative micrographs of KRT23 protein expression in WT and Tlr4-KO mice subjected to sham 
operation or BDL. (c) Gene expression of Krt23 and LPCs markers in WT and Tlr4-KO mice subjected to 
Tsukamoto-French model of ethanol damage (4 weeks, n = 6) compared to uninjured control mice (n = 4).  
(d) Representative micrographs of Krt23 protein expression in WT and Tlr4-KO mice subjected to Tsukamoto-
French model and uninjured control mice. Bars, 100 μ m.
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found that KRT23 was by far the most upregulated gene in this family. Interestingly, KRT23 has been previously 
reported as a biomarker for steatohepatitis44. In the Starmann et al. study, patients with steatohepatitis presented 
an advance degree of fibrosis. Moreover, 5 out of 8 patients with steatohepatitis included in their microarray 
cohort presented ALD. These are common traits between Starmann et al. and the AH cohort of the present study. 
Thus, KRT23 may be expressed in cases of steatohepatitis with cirrhosis.
Because many of the most overexpressed genes in AH are mainly expressed in ductular cell/LPCs, we hypoth-
esized that KRT23 could mainly be expressed in these cells. Our further histological studies in human samples 
and experimental approaches in animal models of ductular reaction strongly suggest that this keratin is mainly 
expressed in the ductular reaction/LPCs population. Our results are in accordance with a recent study from 
Guldiken et al. showing that KRT23 is a maker of mouse and human ductular reaction45. Thus, we used KRT23 
together with other known markers of LPCs (KRT7 and EPCAM) to study the mechanisms leading to the massive 
accumulation of ductular cells in livers with severe AH.
Figure 6. KRT23 regulation by HDACs in mice liver progenitor cells and KRT23 effects on collagen 
synthesis. (a) Effect of HDAC inhibition by NaB administration on Krt23 gene expression in BAML cells  
(3 independent experiments). (b) Gene expression of Sirt1, an HDAC, in a BAML cells treated with NaB  
(3 independent experiments). (c) Correlation between KRT23 hepatic gene expression and COL1A1 hepatic 
gene expression in patients with AH (n = 39). (d) Effect of HDACs inhibition by NaB administration on Col1a1 
gene expression in BAML cells. (e) Silencing of Krt23 by means of siRNA inhibited NaB induced Col1a1 gene 
expression in BAML cells (3 independent experiments).
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It is well known that proliferative bile ductular reaction not only occurs in AH but also in various liver diseases 
including acute-on-chronic liver failure and advanced ALD46. Whether the ductular reaction contributes to liver 
regeneration is still unclear as experimental studies show contradictory results47,48. Using genetic lineage-tracing, 
we previously showed that the biliary compartment probably does not play a role during normal liver homeosta-
sis. However, following profound liver injury, biliary cells give rise to an expanding LPC population that have the 
potential to generate hepatocytes33. Yet, the contribution of the ductular reaction in the regeneration of the failing 
liver in AH is probably minimal. This assertion is based on two previous observations from our research groups. 
First, the accumulation of ductular/LPCs in patients with AH, assessed as the expression of specific cells mark-
ers, closely predicts patient mortality23. In other words, the more ductular cells that accumulate in the liver, the 
worse the patient’s short-term prognosis is. Second, explants from patients that did not respond to corticosteroids 
showed a massive accumulation of ductular cells together with poor hepatocellular function and proliferation24. 
Importantly, in these patients with burn-out AH, bipotent LPCs are mainly engaged to differentiate into a biliary 
phenotype, rather than into hepatocytes. Altogether, these results strongly suggest that the ductular reaction 
does not contribute to the regeneration of dying hepatocytes. On the contrary, it is plausible that accumulation 
of these cells produces deleterious effects such as lobular fibrosis. Our results show that LPCs express collagen 
and support this hypothesis. Interestingly, our immunohistochemistry study in patients with AH revealed that 
some hepatoblasts in the vicinity of the ductular reaction weakly express KRT23. KRT23 expression in hepato-
blasts is also suggested in Guldiken et al.45. This finding suggests that cells derived from LPCs progressively lose 
this marker. However, it is also possible that in the context of AH, stressed hepatocytes undergo reprogramming 
and de novo express keratin including KRT23. Further studies should test this intriguing hypothesis and should 
evaluate the gene expression profile and biological actions of LPCs within the ductular reaction in non-alcoholic 
forms of acute-on-chronic liver failure.
An important finding of our study is that ductular reaction and the consequent KRT23 expression are driven 
by LPS/TLR4. This finding suggests that increased LPS in patients with severe forms of AH could promote ductu-
lar reaction and keratin expression. The fact that LPS levels correlate with KRT23 gene expression and that mice 
lacking Tlr4 have attenuated ductular reaction and keratin expression (Krt23 and Krt7) support this hypothesis. 
Moreover, IL-1ß induces Krt23 gene expression in hepatocellular and bile duct cells lines suggesting an associa-
tion with inflammatory reaction45. There is mounting evidence that LPS plays multiple pathogenic roles in AH 
and is a major driver in this condition21. First, LPS serum levels measured at admission predict multiple organ 
failure, mortality and corticosteroids response in patients with AH20. Second, LPS serum levels correlate with 
neutrophil dysfunction and survival in AH, suggesting that the LPS-TLRs pathway plays a major role in immune 
paralysis in this population49. Third, TLRs mediate the release of inflammatory and fibrogenic mediators from 
immune and non-parenchymal cells caused by gut-derived endotoxin50. All together, these studies indicate that 
targeting LPS translocation from the gut represents an appealing strategy to treat patients with AH.
We also explored other mechanisms regulating KRT23 expression. KRT23 expression is known to be sensitive 
to histone deacetylase inhibition42. We demonstrated that KRT23 gene expression is strongly induced in LPCs 
exposed to exogenous inhibitors of HDACs. To explore if endogenous HDACs also play a role on KRT23 expres-
sion, we focused on sirtuin 1, which we recently showed to be downregulated in patients with AH43. Interestingly, 
KRT23 induction correlated with decreased SIRT1 in a cell model of differentiation of LPCs from stem cells, and 
Krt23 protein expression was increased in Sirt1-KO mice exposed to chronic ethanol. Collectively, our results 
suggest that histone acetylation regulates KRT23 expression in ductular cells. Further studies are needed to inves-
tigate the regulation of ductular KRT23-positive cells through histone acetylation in AH.
Finally, we explored whether KRT23 regulates the biological functions of ductular cells/LPCs. As stated above, 
in patients with AH, cells within the ductular reaction have a highly proliferative phenotype that is probably 
linked to poor differentiation into mature hepatocytes24. Moreover, AH is characterized by pericellular and sinu-
soidal fibrosis, and we previously demonstrated that the stage of fibrosis is significantly associated with 90-day 
survival in these patients31. Therefore, we explored the potential role of LPS-TLR4-KRT23 on collagen expression 
of LPCs. We found that KRT23 regulates the expression of COL1A1 in ductular cells. In fact, several studies indi-
cate that the inhibition of the LPC response to liver injury is associated with a reduction in the severity of hepatic 
fibrosis51,52. The role of collagen production by ductular reaction cells in AH needs to be further explored, as 
myofibrobalsts are probably the main fibrogenic cell type in liver diseases regardless of the origin. Further studies 
should investigate whether targeting these actions in LPCs has beneficial effects in AH.
Our study has potential limitations. First, the exact contribution of ductular cells to liver regeneration in the 
setting of AH is largely unknown. Second, there are no well-established animal models of AH that mimic the 
main findings in humans (i.e. severe fibrosis and cholestasis), since available models only show signs of mild to 
moderate steatohepatitis. To overcome these limitations, we are currently optimizing the isolation procedure 
of single cells from biopsies form patients with AH. Single-cells studies will allow us to further characterize the 
origin and biological properties of ductular cells.
In summary, the present study provides evidence that KRT23, one of the most upregulated genes in AH, is a 
novel marker of ductular cells and correlates with disease severity. Moreover, we found that the LPS-TLR4 path-
way drives accumulation KRT23-positive ductular cells, and that KRT23 which regulates their pro-fibrogenic 
functions in vitro. Further preclinical studies in models of true AH are required to determine if targeting 
KRT23-positive cells is an effective and safe therapeutic strategy to reinstate differentiation of these cells into 
mature hepatocytes and improve liver function.
Methods
Patients. Patients admitted to the Liver Unit of the Hospital Clínic, Barcelona, between January 2007 and 
December 2009 with clinical, analytical and histological features of AH were included in a prospective fashion. 
Experiments were performed with approval and under the accordance of the relevant guidelines established by The 
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Ethics Committee of the Hospital Clinic of Barcelona. All patients included gave written informed consent. The 
inclusion criteria have been previously described10,53,54. Microarray data were deposited in NCBI’s Gene Expression 
Omnibus (GEO; accession number GSE28619). Patients with malignancies or any other potential cause of liver 
disease were excluded from the study. Liver biopsies were obtained using a transjugular approach. A fragment 
of liver tissue, serum and plasma were obtained at the time biopsy. A total of 51 patients with AH were included 
(Table 1). As diseased controls, we included liver tissue from treatment-naïve chronic hepatitis C virus (HCV) 
infection (genotype 1) (n = 10), compensated alcoholic cirrhosis patients without active alcohol intake for at least 
6 months (n = 10) as well as patients with morbid obesity and NASH (n = 14) according to Kleiner’s criteria55. 
Only patients with NASH without evidence of excessive alcohol intake (> 20 gr/d) or other potential cause of liver 
disease were included (Supplementary Table 1). Additionally, as normal controls we included fragments of nor-
mal livers obtained from optimal cadaveric liver donors (n = 3) or resection of liver metastases (n = 4). Criteria 
for selected normal livers have been described in detail previously11.
Comparative Microarray Studies. Comparative analysis of microarray data from patients with AH and 
NASH was performed. Whole transcriptome analysis from these two types of patients was previously performed 
by our group11,30. All microarray studies were performed at the same time using Human Genome U133A plus 
2.0 GeneChip (Affymetrix Hgu133plus, Santa Clara, CA). Differential expression was assessed by using linear 
models and empirical Bayes moderated t-statistics. Linear Models for Microarray Analysis (LIMMA) R-package 
software was used for the analysis of gene expression microarray data56. Group comparisons and determinations 
of false discovery rates (FDR computation using Benjamini-Hochberg procedure)57 were performed. Functional 
analysis of gene expression data was conducted using the R/Bioconductor package GOstats and the GO database 
(http://www.geneontology.org). Only genes that could be associated with a unique EntrezGene ID were used. 
Among them those were selected representing a change of 1.5-fold or greater and moderated p-value < 0.05. The 
hypergeometric distribution was used to evaluate the probability of randomly observing the enrichment for each 
GO term58.
Experimental Models of Liver Injury and Progenitor Cell Expansion in Mice. The current experi-
mental models of ALD do not reproduce the main histological features of severe AH but rather mimic moderate 
alcoholic liver disease32. Through the study we used different animal models to better mimic particular features 
of AH. All mice used were male.
To investigate the effects of the LPS-TLR4 pathway in KRT23 induction we used a model of acute liver injury 
(LPS) and advanced fibrosis (CCl4 followed by a single dose of LPS)11. Male 8-week-old Balb/c mice were pur-
chased from Charles River (Charles River, l’Arbresle, France). For the acute liver injury model mice were injected 
LPS (Sigma-Aldrich) intravenously at a dose of 10 mg/kg body weight (n = 6) or saline as control (n = 6) and were 
sacrificed 4 hours after the injection. For the advanced fibrosis model, mice were injected carbon tetrachloride 
(CCl4) intraperitoneally (diluted 1:4 in corn oil; Sigma-Aldrich, St Louis, MO) at a dose of 0.5 ml/kg body weight 
twice per week for a total of 5 injections. Control mice (n = 6) were given vehicle (corn oil, Sigma-Aldrich). CCl4 
treated mice were injected intravenously either LPS at a dose of 10 mg/kg body weight (n = 8) or saline as control 
(n = 6) and were sacrificed 4 hours after the injection.
A model of ductular reaction expansion was induced by administering a 0.1% 3,5-diethoxycarbonyl-1,4-d
ihydro-collidin (DDC) diet for 3 weeks (n = 6). LPCs and non-LPCs cells were isolated by liver perfusion method 
from Hnf1β CreER/R26RYfp uninjured and from mice treated with a DDC containing diet (Sigma-Aldrich) for 3 
weeks as previously described33.
Pathogen-free 8-week-old male TLR4-KO mice (originally generated by Dr. Shizuo Akira, Osaka University, 
Japan), and wild-type (WT) littermates were subjected to a model of ductular reaction (BDL) or to a model of 
alcoholic steatohepatitis (Tsukamoto-French)59. Briefly, the murine TLR4 genomic clone was screened from the 
129/SvJ mouse genomic library (Stratagene, La Jolla, CA). A targeting vector was designed and electroporated 
into E14.1 embryonic stem cells. Two embryonic stem cell clones were selected for microinjection into blasto-
cysts. These clones gave germline transmission and were interbred to generate homologous gene targeted mice. 
TLR4 knowckout mice were backcrossed at least 10 generations onto the C57BL/6 background. Bile duct ligation 
(BDL) was performed as described previously50,60. Bile duct ligated and sham-operated mice (n = 3) were sacri-
ficed 5 (n = 4) or 21 (n = 8) days after surgery. Tsukamoto-French model of continuous ethanol infusion in mice 
was performed in as described previously50,61. Ethanol infusion was increased until it reached 29.4 g/kg/day at 4 
weeks (n = 6; control mice n = 4).
A model of chronic plus single binge ethanol in Sirt1-KO mice was used to explore the role of HDACs as 
modulators of KRT23 expression. Liver-specific sirtuin KO mice (Sirt1-KO) (n = 6) mice and their age-matched 
WT littermates (n = 6) were subjected to a model of chronic plus single binge ethanol consumption as previously 
described (NIAAA model)43. Sirt1 allele with floxed exon 4 was backcrossed 5 times into the C57BL/6 back-
ground. It was then bred with mice expressing the Cre recombinase driven by the albumin promoter to generate 
liver specific Sirt1 knockout mice (Sirt1 LKO) in over 98% C57BL/6 background. SIRT1 LKO mice and their 
age-matched littermate Lox controls (Cre−/−, Sirt1 flox/flox) older than 6-week of age were used in the present study. 
All animal procedures were approved by The University of North Carolina at Chapel Hill Institutional Animal 
Care and Use Committee and were conducted in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals.
Cell cultures and in vitro assays. To investigate the effect of LPS on ductular cells, the NIH-approved 
human pluripotent stem cells line H1 (WA01, WiCell Research Institute, Wisconsin, MA) underwent differen-
tiation following The National Institutes of Health Guidelines on Human Stem Cell Research, as described pre-
viously62. Briefly, differentiation of H1 PSCs cells was induced by culturing the cells in priming medium (media 
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formulation described in Supplementary methods). After 72 hours, differentiation medium was added for 5 days. 
At day 8, cells were cultured in maturation and maintenance medium for 8 days. Cells were collected for RNA and 
protein extraction as well as immunofluorescense analysis after 5 days in differentiation medium and after 8 days 
in maturation medium. Thirty-six hours before harvest, cells were treated with LPS (1 μ g/mL, Sigma-Aldrich) or 
phosphate buffered saline (PBS, Sigma-Aldrich).
BAML cells were isolated from control mice as previously described63 and were maintained on type-I 
collagen-coated plates in MCDB201/DMEM medium. BAML cells were treated with the HDAC inhibitor sodium 
butyrate (NaB, 4 mM, Sigma-Aldrich) for 24 h in fresh culture medium. Transfection with either scrambled or 
KRT23 small interfering RNA (siRNA; Life Technologies) was performed for 24 h and followed by treatment with 
4 mM NaB for 24 h in fresh culture medium. Lipofectamine® 3000 reagent (Life Technologies) was used accord-
ing to the manufacturer’s instructions. Transduction experiments with adenovirus vectors containing either a 
specific human KRT23 sequence (Ad-KRT23) or a GFP sequence (Ad-GFP)(SignaGen Laboratories, Rockville, 
MD) incubated in cell culture media for 12 h were performed on human HepaRG cells (Life Technologies).
Analysis of Serum KRT23 levels. Samples from patients with AH (n = 37) and compensated alcoholic 
cirrhosis (n = 14) were analyzed. To detect KRT23 serum levels, serum samples were collected from patients and 
stored at − 80 °C. Serum samples were analyzed using commercially available immunoassays for KRT23 detection 
(CSB-EL012539HU ELISA kit; Cusabio, Wuhan, China). LPS serum levels were determined using the limulus 
amoebocyte lysate QCL-1000 test (Lonza Walkersville Inc, Walkersville, MA).
Statistics. Continuous variables were described as means (± standard error) or medians (interquartile range). 
Comparisons between groups were performed using the Student’s t test or the Mann-Whitney U test, depend-
ing on their normality test. Differences between categorical variables were assessed by Fisher’s exact test or the 
chi-square test with Yates correction for continuity, when necessary. Correlations between variables were eval-
uated using Spearman’s rho or Pearson’s r, when appropriate. The area under the receiver characteristic curve 
(AUROC) analysis was used to determine the best cut-off value and the accuracy (sensitivity and specificity) 
of continuous variables associated with 90-day mortality. A comparative risk analysis was performed using the 
Kaplan-Meier method. Comparisons were performed by the log-rank test. All statistical analyses were performed 
using SPSS version 14.0 for Windows (SPSS Inc., Chicago, IL).
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